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ABSTRACT 
Objective: The current research was structured to achieve a maximum topical delivery for the drug clobetasol-17-propionate (CP) and to predict 
the effects of various independent variables like lipid: drug ratio, surfactant, and homogenization time on particulate characters and performance 
solid lipid nanoparticles (SLNs).  
Methods: CP loaded SLNs were formulated by Emulsification–Homogenization method and optimized using 33 full factorial designs (Design-Expert 
software 11.0). Drug loaded SLNs were evaluated for various parameters like particle size, surface charge, polydispersity index, entrapment 
efficiency, surface morphology, thermal analysis, in vitro drug release through skin (Franz diffusion cell), drug deposition study and stability.  
Results: The optimized formulation (SLNs) attains a minimal Particle size of 133.3±3.66 nm, Poly dispersibility index of 0.179±0.081, % 
entrapment efficiency of 78.1±1.11 and Zeta potential of-36.2±0.11mV. Skin permeation study of CP loaded SLNs suspension showed prolonged 
drug release up to 24h. Maximum drug deposition was obtained after developing the drug into SLNs (48.22µg/ml) when compared to the pure drug 
(19.12µg/ml).  
Conclusion: SLNs were promising colloidal particulate carriers by which prolonged drug release and improved skin permeation was achieved for 
the drug Clobetasol 17- propionate. 
Keywords: Clobetasol-17-propionate, Solid lipid nanoparticles, 33 full factorial design, Franz diffusion cell 




Psoriasis is a consistently recurring autoimmune disorder of skin 
characterized by relapsing episodes of inflammatory lesions and 
hyperkeratotic plaques on the skin with globally occurrence of 
around 2–5%. The classification of psoriasis was done on the basis 
of extent of inflammation on skin, localization of rash, severity of the 
patient condition, and other. Amongst these, the occurrence of 
chronic plaque psoriasis (CPP) was major in occurrence proportion 
with equivalent likelihood in both sexes and early onset before the 
age of 35 y [1]. Psoriasis is a disease caused by a multitude of both 
genetic and environmental factors such as trauma, drugs, infection, 
alcohol, smoking and stress but its accurate origin is still not known 
[2]. Among the currently available treatments including topical 
therapy, phototherapy and systemic therapy, none of the treatment 
for psoriasis was found to be safe, effective and able to completely 
cure the disease [3]. The lack of effective and safe treatment for 
psoriasis paved a way to develop and implement novel approach 
with a view to make the therapy more useful and acceptable. Unlike 
normal skin, pathological progression of psoriasis was supposed to 
depend on a multitude of coherent events involving the activation of 
circulating immune cells and their secreted signaling molecules like 
cytokines, chemokines and growth factors. All these events further 
progress to mark hyperkeratosis, congealing of epidermis and 
neovascularization [5]. Currently, Glucocorticoids (GCs) are highly 
effective for the treatment of inflammatory diseases. It is currently 
approved for topical use in different dosage forms such as cream, 
solution, and ointment [6]. The Reported Adverse Drug Reactions 
(ADRs) with conventional dosage forms include atrophy of skin, 
steroid acne, hypopigmentation around the application site, allergic 
contact dermatitis, Cushing like syndrome and osteonecrosis [7]. 
SLNs have been widely used for topical delivery due to their 
effective interaction with skin layers, and enhance skin permeation. 
SLNs were formulated by using different techniques such as high-
speed homogenization and ultrasonication etc., [8]. SLNs were 
comprised of biocompatible solid lipid, surfactant and drug. The 
drug is usually loaded in the matrix of lipid which is coated by a 
nontoxic surfactant and in the form of solid dose at room and body 
temperatures [9]. The suitability of bio-degradable lipids for 
dermatological applications was also confirmed by successful 
formulation of lipid-based delivery systems for the management of 
dermal disorders [10].  
The aim of the present work was to develop and optimize solid lipid 
nanoparticles using design expert software and to explore the in 
vitro characterization of the optimized formulation for particle size, 
poly dispersibility index (PDI), percentage entrapment efficiency (% 
EE), transmission electron microscopy, differential scanning 
calorimetry (DSC) and drug release studies. The impact of the carrier 
type on various critical attributes of a drug such as extent of CP 
delivery into the epidermis and dermis via an in vitro method for 
utilizing UV spectroscopy and stability of the developed formulation 
was also evaluated. 
MATERIALS AND METHODS 
Clobetasol-17-propionate was purchased from Yarrow Chemicals 
(Mumbai, India). Compritol 888 ATO was a kind gift from Gattefossé 
(France). Tween 80 as a surfactant, poloxamer 188 as a stabilizer, 
Methanol, and Acetone, were purchased from Sigma–Aldrich (India). 
Distilled water was obtained from the in-house distillation system. 
Preparation of CP-loaded SLNs 
SLNs were prepared by the emulsification-homogenisation method. 
Formulation procedure was divided into two parts in which one part 
contained drug and lipid, while the second part contained an 
aqueous solution of surfactant and stabilizer. Drug and lipid mixture 
was melted 5 °C above the melting point of lipid. Aqueous phase was 
heated to same temperature as like lipid phase. When both parts 
attain equilibrium, the aqueous phase was incorporated into lipid 
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phase and emulsified using high-speed homogenizer (IKA® T-10 
basic Ultra-Turrax®, Germany) at 10,000 rpm for 15 min. The 
obtained emulsion was ultrasonicated using a probe Sonicator 
(VibracellTM 700W; Sonics, USA) at 80% amplitude and duration of 
5 min. Cycles were repeated alternately until it attains uniform 
particle size. The resulting nanoemulsion was cooled down in an ice 
bath to produce nanoparticle dispersion. Different formulations 
were prepared by varying the critical process variables [11]. 
Experimental design 
In the present work, 33 factorial designs were chosen for the 
optimization of CP SLN using Design-Expert software (Trial Version 
11, Stat Ease Inc., and USA). 3 factors were chosen and the responses 
were measured at 3 levels. Totally 30runs were designed randomly. 
The design consisted of replicated center points and a set of points 
lying at the midpoints of each edge of the multidimensional cube. 
This defines the region of interest used to evaluate the main effects, 
interaction effects, and quadratic effects of the formulation 
ingredients, and to optimize the formulation. The quadratic model 
generated by the design was:  
Y=A0+A1X1+A2X2+A3X3+A4X1 X2+A5X2 X3+A6X1 X2+A7X12+A8X22+A9X32 
In which Y is the measured response of the dependent variables 
associated with each factor-level combination; A0–A9 are the 
regression coefficients of the respective variables and their 
interaction terms computed from the observed experimental values 
of the measured response. X1–X3 are the codes for independent 
variables. Independent variables selected were a concentration of 
drug: lipid (X1), concentration of surfactant (X2) and the high-speed 
homogenization (X3). Independent variables were represented by 
level-1, 0 and+1 correspondings to the low, middle, and high values 
respectively. The measured responses Y1 = particle size (PS) and Y2 = 
Polydispersity index and Y3 = entrapment efficiency (%EE) with 
constraints were described in [table 1]. 
 
Table 1: Selection of independent variables and their levels chosen for the execution of 33 factorial designs 
Types of variable independent variable Levels 
Low (-1) Medium (0) High (+1) 
X1=Drug: lipid Ratio(D: L)(%w/w) 1:3 1:4 1:5 
X2=Surfactant concentration(S)(%w/w) 2 3 4 
X3=HSH Time (HT) (min) 5 10 15 
Dependent variable 
Y1=Particle Size(nm), Y2=Poly Dispersibility Index, Y3=%Entrapment Efficiency 
 
33 factorial designs were employed for the study. Further 3D 
response surface plotted for depicting the effects of the 
predetermined factors on the measured responses. 3D response 
surface plots are helpful in explaining the relationship between 
independent variables and dependent variables. When these plots 
are carefully observed, the qualitative effect of each variable on each 
response parameter could be visualized. 
Characterization of CP SLNs 
Particle size, polydispersity index and zeta potential 
measurement 
Particle size, polydispersity index (PDI) and zeta potential of the 
SLNs were measured by dynamic light scattering technique using 
Malvern Zetasizer Nano ZS90 (Malvern Instruments, UK). CP SLNs 
colloidal dispersions were diluted 10 times with double distilled 
water. Particle size and PDI measurements were performed by 
taking 1 ml of the diluted formulation into polystyrene cuvettes and 
disposable folded capillary cell for zeta potential at 25 °C,to ensure 
that the light scattering intensity was within the instruments 
sensitivity range. Each sample was analyzed in triplicate and the 
results were shown as mean±standard deviation. 
% Entrapment efficiency 
The entrapment efficiency (%EE) of formulated CP SLN was 
determined by measuring the concentration of unentrapped drug in 
the lipidic dispersion by using the centrifugation method. The SLNs 
Samples were subjected to centrifugation at 10000 rpm for 15 min 
(Remi Centrifuge Pvt. Ltd., India) and the amount of Clobetasol 
propionate Supernatant was collected, suitably diluted with 
methanol and analyzed for free drug content by UV spectroscopy at 
239 nm. %EE was calculated by following equation. 
%EE =
Total amount of CP − Amount of free CP
Total amount of CP
× 100 
Each value was measured in triplicate. The results are shown as 
mean±standard deviation. 
Differential scanning calorimetry (DSC) analysis 
DSC analysis was done to predict the compatibility between drug 
and excipients. Blank SLNs, drug-loaded SLNs and physical mixtures 
were subjected to DSC analysis (V24.9 build 121, TA instrument, 
USA). Briefly, blank SLNs and CP SLNs samples were lyophilized 
prior to DSC analysis. Samples (4–5 mg) were kept in the standard 
aluminum pans and sealed. Then the pans were placed under the 
isothermal condition at 25±1 °C for 10 min. DSC analysis was 
performed at 10 °C/min from 25 to 300 °C under a nitrogen 
atmosphere at a flow rate of 50 ml/min. An empty aluminum sealed 
pan was used as a reference. 
Transmission electron microscopy 
The morphological characters of CP loaded SLNs were observed with 
transmission electron microscopy (TEM; Philips, Tecnai 20, Holland). 
A drop of the diluted sample was placed on the surface of carbon-
coated copper grid and stained with a drop of 1% (w/w) aqueous 
solution of phosphotungstic acid (negative stain) for 30s. Excessive 
staining solution was washed out by filter paper and a thin aqueous 
film was left on the surface. After staining, samples were dried at room 
temperature for 10 min to perform out investigation [16]. 
In vitro release study 
In vitro release studies of CP loaded SLNs and plain CP suspension was 
carried out using modified Franz diffusion cell with a receptor volume 
capacity of 12.5 ml using cellulose acetate membrane (MWCO-12 000–
14 000 Da, pore size-2.4 nm, HIMEDIA, Mumbai, India) and PBS of pH 
7.4 as a dialyzing medium. The membrane was soaked in double-
distilled water for about 12 h, prior to mounting the membrane 
(diffusion area 1.95 cm2) in the Franz diffusion cell. The pretreated 
membrane was placed on the modified Franz diffusion cell filled with 
phosphate buffer (pH7.4) in the receptor compartment. The whole 
assembly was placed on the magnetic stirrer at 350 rpm and 
temperature was maintained at 32.0±0.5 °C. The samples (plain drug 
suspension and CP loaded SLNs dispersion) equivalent to 2 mg drug 
were kept over the membrane in donor compartment and stirred. 
Samples were withdrawn from the receptor compartment at 
predetermined time intervals (0, 6, 8, 10, 12 and 24 h) and the same 
volume was refilled with diffusion medium. The samples were 
analyzed using UV spectrophotometer at 239 nm after appropriate 
dilutions. Percent drug release was calculated and graph was plotted 
between percent drug releases against time. Release studies were 
performed in triplicate for each formulation. 
Ex-vivo diffusion study 
Ex-Vivo diffusion studies were carried out to evaluate the 
distribution of CP delivered through CP loaded SLNs suspension and 
plain CP suspension using sheepskin. Sample of sheepskin was 
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obtained from the local slaughterhouse (Tirupati, Andhra Pradesh). 
The skin diffusion studies were performed using the Franz diffusion 
cells according to this method. Skin samples were separately treated 
with the formulations (plain CP suspension and CP loaded SLNs) 
containing drug equivalent to 400 mg (6h with each test 
formulation). At the end of the experiment, the skin samples were 
washed and removed from the Franz cells. Epidermal and dermal 
layers were manually separated using tweezers. CP was extracted in 
10 ml methanol by homogenization of each skin layer and extracted 
samples were assayed for CP concentration using UV spectroscopy 
at 239 nm [12]. 
Stability studies 
The stability of the developed CP SLNs formulation was evaluated 
for 3 mo with reference to ICH guidelines and samples were stored 
in sealed amber colored glass vials at 4 °C. After 3 mo, the samples 
were characterized with respect to particle size, ZP, PDI, EE, and 
drug loading. 
RESULTS AND DISCUSSION 
Statistical analysis of formulations 
Results obtained from all the formulations were analyzed using 
Design-Expert® Version 11.0 software [table 2]. Response surface 
plots were generated using the software and new formulations with 
desired responses were obtained by a numerical optimization 
technique. The responses obtained were used to study the effect of 
independent variables. A quadratic model was suggested for particle 
size, PDI, % entrapment efficiency. The list of solutions suggested by 
the software was sorted in the descending order of the desirability 
and the solution which fulfills the required criteria was reported. 
The factors which had a significant effect on the responses were 
identified using Analysis of variance (ANOVA). To evaluate the 
chosen experimental design, the optimized formulation was 
prepared as per the solutions obtained and subjected to evaluation 
parameters. The resulting experimental values were compared with 
predicted values. 
 
Table 2: Layout of 33 full factorial design showing the values of dependent variables of 30 possible CP SLNS formulations 
Run X1 X2 X3 Y1 Y2 Y3 
1 5 3 5 245.2±3.21 0.328±0.061 70.9±3.11 
2 4 3 15 173.4±2.23 0.352±0.025 52.6±2.63 
3 3 4 15 251.7±4.21 0.432±0.039 39.8±3.12 
4 4 2 10 168.3±1.11 0.222±0.042 68.3±2.58 
5 3 3 5 221.9±3.55 0.307±0.064 55.7±2.64 
6 4 3 10 140.2±3.71 0.212±0.023 75.3±3.13 
7 5 3 10 200.9±5.63 0.284±0.035 78.1±3.45 
8 3 4 10 212.2±3.08 0.309±0.045 52.7±3.63 
9 4 3 10 135.3±2.05 0.189±0.083 77.1±3.86 
10 4 4 10 225.1±1.32 0.321±0.057 55.8±2.45 
11 5 2 15 246.7±2.56 0.445±0.062 58.8±3.12 
12 4 2 15 183.9±2.05 0.404±0.039 48.2±2.69 
13 5 2 10 230.6±4.12 0.262±0.056 72.2±3.56 
14 3 4 5 280.2±3.98 0.373±0.066 47.2±4.12 
15 3 2 10 189.2±4.21 0.247±0.089 59.71±3.23 
16 4 2 5 241.1±3.26 0.295±0.056 57.5±2.36 
17 5 4 5 306.8±4.25 0.395±0.063 60.7±3.65 
18 3 3 10 175.4±2.35 0.251±0.052 64.1±4.10 
19 4 4 15 262.2±3.97 0.457±0.061 46.3±3.25 
20 4 3 10 140.5±2.18 0.235±0.073 74.5±2.53 
21 4 3 5 202.6±4.91 0.257±0.069 65.1±3.22 
22 4 4 5 286.3±4.72 0.38±0.056 51.2±4.12 
23 4 3 10 133.3±3.66 0.179±0.081 78.1±1.11 
24 3 3 15 190.2±2.15 0.377±0.071 44.3±4.23 
25 5 2 5 288.7±4.13 0.326±0.082 63.2±3.22 
26 5 4 10 240.6±3.23 0.300±0.071 66.6±2.12 
27 5 4 15 252.0±2.06 0.440±0.065 54.5±2.81 
28 5 3 15 224.0±3.22 0.401±0.059 60.1±3.24 
29 3 2 15 190.1±4.89 0.425±0.063 42.2±3.88 
30 3 2 5 261.5±5.01 0.310±0.077 53.1±3.26 
*All values are expressed as mean±SD, n=3 
 
Effect on particle size 
The particle size varied for all the formulations were ranging 
between 133.3 nm (formulation 23) to 306.8 nm (formulation 
17) at various factor-level combinations. The independent 
factors (variables) affecting the particle size were concentration 
of lipid, concentration of surfactant and hominization speed on 
particle size was studied, and the responses obtained are given 
in [table 2]. The suggested quadratic model with F-value of 39.03 
implies that the model is significant. The model P-value 
was<0.0001 indicated that the model terms are significant. P 
values for, lipid to drug ratio was 0.0002, surfactant 
concentration was<0.0001 and that for hominization time 
was<0.0001. These results indicated there was no significant 
affect in particle size with the change in independent variables. 
The regression coefficient value R2 was 0.9461, adjusted R2 was 
0.9219 and predicted R2 was 0.8652 indicating minimum 
variations in the experimental model. The adequate precision 
ratio, measuring the signal to noise ratio was 20.407 indicating 
an adequate signal. A ratio greater than 4 is desirable, and this 
model can be used to navigate the design space. The polynomial 
equation in terms of coded factors is given below. 
Particle size: 145.83+14.62A+17.61B-20.01C-5.82AB+1.13AC+ 
5.27BC+27.69A2+45.91B2+44.46C2 
The individual factor A, lipid to drug ratio had a positive effect on 
particle size as showed by the positive coefficient estimate value. 
The particle size increased with the ratio of lipid to the drug, 
whereas surfactant concentration showed a positive effect and 
homogenization time showed a negative effect. The combined effect 
of lipid to drug ratio and surfactant concentration was negative, 
whereas the homogenization time with lipid to drug ratio and 
surfactant concentration showed a positive effect. An increase in the 
particle size was observed with a concomitant increase in the 
proportion of lipid and reduction in the surfactant concentration. 
Larger particle size with 5:1 lipid to drug ratio could be attributed to 
the increased viscosity of the system due to higher lipid 
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concentration. Another possible explanation to this may be a film of 
loosely arranged surfactant molecules at the interface of the two 
layers in Nano dispersion due to the lower concentration of 
surfactant in comparison to the lipid. On the other hand, lower lipid 
with higher surfactant resulted in fine Nano dispersion with smaller 
sized particles. The size of SLN decreased with increase in 
homogenization time. This could be due to the shear energy induced 
by homogenization. The effect of lipid: drug ratio, sonication time 
and surfactant concentration on the particle size is presented in the 
form of response surface plots in [fig. 1]. 
  
 
Fig. 1: 3D response surface plot for effect of lipid: drug ratio, homogenization time and surfactant concentration on particle size 
 
Effect on PDI 
The suggested quadratic model with F-value of 44.89 implies that 
the model is significant. The model P-value was<0.0001 indicated 
that the model terms are significant. P values for, lipid to drug ratio 
was 0.1083, surfactant concentration was<0.0001 and that for 
hominization time was<0.0001 the results indicated there was no 
significant difference in PDI with the change in hominization time. 
The regression coefficient value R2 was 0.9528, adjusted R2 was 
0.9316 and predicted R2 was 0.9059 indicating minimum variations 
in the experimental model. The adequate precision ratio, measuring 
the signal to noise ratio was 20.160 indicating an adequate signal. A 
ratio greater than 4 is desirable, and this model can be used to 
navigate the design space. The polynomial equation in terms of 
coded factors is given below. 
PDI: 0.2131+0.008A+0.026B+0.042C-0.002AB-0.0006AC-0.013BC+ 
0.026A2+0.048B2+0.1089C2 
As per the polynomial equation, the effect of lipid to drug ratio, 
surfactant concentration and homogenization time was shown a 
positive effect. All the interaction effects showed a negative 
coefficient estimate value indicating the indirect relationship with 
the PDI. It was observed that when 4% w/w tween 80 was used, PDI 
was increased [Table 2]. This was because; during homogenization 
process alkyl chain of the surfactant molecule covers the surface of 
lipid particle via hydrophobic interaction to form a stable lipid 
matrix. Once this stable matrix is formed, excess surfactant may lead 
to accumulation of surfactant particles on the surface of stable lipid 
matrix causing increase in PDI as was observed in the form of 
response surface plots in [fig. 2]. 
 
 
Fig. 2: 3D response surface plot for effect of lipid: drug ratio, homogenisation time and surfactant concentration on polydispersity index 
 
Effect on % EE 
The suggested quadratic model with F-value of 45.47 implies that 
the model is significant. The model P value was<0.0001 indicated 
that the model terms are significant. P values for, lipid to drug ratio 
was 0.0001, surfactant concentration was 0.0008 and that for 
hominization time was<0.0001 the results indicated there was no 
significant difference in %EE with the change in hominization time. 
The regression coefficient value R2 was 0.9534, adjusted R2 was 
0.9324 and predicted R2 was 0.8971 indicating minimum variations 
in the experimental model. The adequate precision ratio, measuring 
the signal to noise ratio was 25.75 indicating an adequate signal. A 
ratio greater than 4 is desirable, and this model can be used to 
navigate the design space. The polynomial equation in terms of 
coded factors is given below. 
Entrapment efficiency (%): 73.28+7.02A-2.69B-4.32C+0.242AB+ 
0.691AC+0.508BC-0.911A2-8.56B2-13.00C2 
The results for drug entrapment in solid lipid nanoparticle 
formulations were shown in table 4. The term A, lipid to drug ratio 
showed a positive coefficient estimate value indicating the direct 
relationship with the entrapment efficiency, whereas surfactant 
concentration and homogenization time showed a negative effect. 
The interaction effect of lipid to drug ratio with surfactant 
concentration and homogenization time showed a positive effect. 
Formulation with lipid: drug ratio of 4:1 showed greater drug 
entrapment, i.e., 78.1%. A higher %EE could be due to the 
presence of higher amount of lipid which provides additional 
space for a drug molecule to embed in, thereby increasing total 
surface area. [table 2] This can lead to reduction in the diffusion 
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rate of the solute molecule as the viscosity of the lipidic phase is 
higher and thus showed higher %EE s compared to others. % EE 
was found to increase with the increasing amount of lipid to drug 
molar ratio. Thus, % EE was found to be mainly dependent on the 
drug: lipid ratio of the formulation. [fig. 3] represents the response 
surface plots depicting the effect of various factors on % EE. 
 
 
Fig. 3: 3D response surface plot for effect of lipid: drug ratio, homogenisation time and surfactant concentration on entrapment efficiency 
 
Optimization and validation 
The desirability function was investigated using Design-Expert 
software to acquire the optimized formulation. The set criteria for the 
optimization were a minimum size of solid lipid nanoparticles, 
optimum Polydispersibility index, and maximum entrapment 
efficiency of drug. The solutions generated by the software were 
sorted in the descending order of the desirability and the formulation 
with highest desirability factor was considered for further formulation 
[fig. 4]. The predicted values were compared with actual values by 
calculating the relative error. The relative error was found to be less 
than 5% indicating a minimum variation in the batch [table 3]. 
 
 
Fig. 4: Desirability for the effect of lipid: drug ratio, homogenisation time and surfactant concentration 
 
Table 3: Predicted and observed responses for the optimized formulation 
Factor 1 





Responses Observed Predicted Relative error (%) 
3.64 2.71 14.03 Ps(nm) 153.81±10.1 155.02±9.21 1.21 
   PDI 0.318±1.35 0.320±0.12 0.002 
   %EE 58.53±3.53 60.21±2.31 1.68 
*All values are expressed as mean±SD, n=3 
 
Mean particle size, polydispersity index, zeta potential, percent 
entrapment efficiency 
The mean particle size of optimized CP loaded SLNs was found to be 
133.3±3.66 nm with PDI to 0.179±0.081 [table 2]. The ZP of the 
optimized formulation was found to be-36.2±0.11 mV. The zeta 
potential value of selected batch indicated the stable formulation. 
High ZP (negative or positive) indicates stable nanoparticle 
dispersion as highly charged particles are responsible for the 
prevention of aggregation of the particles due to electric repulsion. 
%EE of the optimized formulation was found to be 78.1±1.11%. High 
entrapment can be attributed due to the lipophilic nature of drug 
having higher affinity for the selected lipid matrix. 
Characterization of optimized solid lipid nanoparticle 
Transmission electron microscopy 
Size and shape of the optimized batch of nanoparticles were 
evaluated by TEM. TEM images of the SLNs confirmed the oval and 
nearly spherical shape of nanoparticles with narrow size 
distribution. They further confirmed non aggregation of 
nanoparticles [fig. 5]. The diameters of the nanoparticles observed in 
the micrographs were in good agreement with data obtained from 
Malvern particle size analyzer. 
Differential scanning calorimetry 
DSC is a tool to investigate the melting and recrystallization behavior 
of crystalline material like SLNs 13. Fig. 6 shows the DSC thermograms 
of pure CP, Compritol 888 ATO, physical mixture of CP and Compritol 
888 ATO, and CP loaded SLNs. Compritol 888 ATO exhibited a sharp 
endothermic event ascribing to the melting point around 75.41 °C [fig. 
6a]. Pure CP showed a sharp endothermic peak at 196.24 °C 
corresponding to its melting point, indicating its characteristic 
crystalline nature [fig. 6b]. These sharp melting endothermic peaks of 
bulk lipid and drug indicated that the starting materials were 
crystalline. Characteristic peak for CP was completely absent in 
lyophilized CP loaded SLNs [fig. 6d], while it was clearly evident in 
Reddy et al. 
Int J App Pharm, Vol 11, Issue 5, 2019, 143-150 
148 
physical mixture of CP (196.24 °C) and Compritol 888 ATO 75.41 °C as 
showed in [fig. 6c]. It has been reported that when the drug does not 
show its endothermic peak in the CP SLNs formulations, it is said to be 
in the amorphous state [14]. Hence, it could be concluded that the drug 
was present in the amorphous phase and might have been 
homogeneously dispersed in the SLNs. 
 
 
Fig. 5: CP loaded SLNs (formulation no. 23) visualized by transmission electron microscopy. (a) Overall view showing particle 
polydispersity, (b) magnified view showing particle internal structure 
 
 
Fig. 6: DSC study. (a) Pure Compritol 888, (b) pure CP, (c) physical mixture of CP and Compritol 888 ATO (d) CP loaded SLNs 
 
 
Fig. 7: In vitro drug release profile from pure CP suspension and CP loaded SLNs suspension in phosphate buffer (pH 7.4), * All values are 
expressed as mean±SD, n=3 
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In vitro release study 
The cumulative percentage release of CP from plain CP suspension 
and CP loaded SLNs suspension was investigated in vitro over a 
period of 24h. Each sample was analyzed in triplicate and release 
curves have been shown in [fig. 7]. The drug release from plain CP 
suspension was faster with 93.77±4.04% release of CP within 7h. On 
the other hand CP loaded SLNs suspension depicted a biphasic 
release pattern with relatively faster initial burst release followed by 
comparatively slower release with 69.90±2.60% release of CP after 
24h. Burst release can be useful to improve the penetration of the 
drug, while sustained-release supplies the drug over a prolonged 
period of time. Regarding the drug release profiles, CP loaded SLNs 
and plain CP suspension followed Higuchi release kinetics (r2 = 
0.989) and zero-order release kinetics (r2 = 0.981), respectively. 
Similar results for novel and conventional formulation were 
obtained [17]. 
Ex-vivo diffusion study 
The ability of CP loaded SLNs suspension and pure CP suspension to 
deliver CP across sheepskin was evaluated. UV spectroscopy was 
used to quantify CP in the epidermis, dermis, and receptor. As shown 
in [fig. 8], plain CP suspension delivered the maximum amount of CP 
in the receptor compartment (145.78µg/ml) with minimum amount 
of CP in the epidermis (19.12µg/ml) and dermis (36.56µg/ml) when 
examined though 1 cm2 diffusion areas. This indicated maximal 
distribution of drug in systemic circulation after 6 h. At the same 
time CP loaded SLNs suspension delivered its maximum amounts of 
CP into the epidermis (48.22µg/ml), which is the location of the 
over-proliferation of keratinocytes and development of psoriasis.
 
 
Fig. 8: In vitro skin distribution study of pure CP loaded suspension and CP loaded SLNs 
 
Moreover, the minimum amount of CP was found to be present in the 
dermis (18.34µg/ml) and in the receptor compartment (8.16µg/ml) of 
the Franz cell, demonstrating the potential of CP loaded SLNs to limit 
systemic escape of the steroidal drug. In addition, the results of skin 
distribution study demonstrated that CP loaded SLNs suspension 
possesses the ability to efficiently deliver the drug with limited 
systemic escape and could be considered as an appropriate carrier for 
topical therapy of psoriasis. Based on skin distribution data reported 
that CP delivery to the skin could be related to the increased solubility 
of drug in the lipid matrix (in case of SLNs) which in turn results into 
high concentration gradient at the skin surface [15]. It is assumed that 
due to the lipid-rich environment of the epidermis, lipophilic 
compounds, like CP, may remain a drug depot in the intercellular 
space of epidermal cells, allowing slow drug permeation into the lower 
viable epidermis where psoriasis originates. In the SLN based 
formulation, CP largely resides in the epidermis (topical delivery) 
because of the enhanced hydrophilicity of the epidermis which limits 
significant partitioning of hydrophobic drug. Moreover, it is well-
known that skin in diseased condition, particularly in case of psoriatic 
skin, becomes more permeable than healthy skin. Hence, inpatients, 
more deposition of CP in the epidermis is expected which makes CP 
loaded SLNs more effective. 
Stability study 
Stability studies were carried out according to assess the stability and 
integrity of CP loaded SLNs [11]. The CP loaded SLNs showed minor 
enhancement of particle size and PDI with a slight reduction of ZP and 
%EE after 3 mo storage at 4 °C Percent change in PS and %EE were 
2.91% and 3.15% respectively on 3 mo storage of SLNs formulation. 
The changes were insignificant which indicates excellent physical 
stability of the SLNs during their storage at 4 °C for 3 mo. 
CONCLUSION 
CP loaded SLNs were prepared using Compritol 888 ATO as lipid 
matrix, poloxamer-188 as stabilizer employing the emulsification-
homogenisation technique. The important parameters like drug: 
lipid ratio, surfactant concentration and homogenization time were 
optimized by 33 full factorial design to obtain a minimal PS, Narrow 
PDI and highest % EE. Thus, desirable goals could be achieved by 
systematic formulation approach the shortest possible time with 
reduced number of experiments, The maximum zeta potential of-
36.2±0.11 mV was attributed to the anionic nature of the lipid 
matrix and indicated, physical stability of the CP SLNs. DSC studies 
confirmed the absence of any interaction between CP and lipids. 
TEM imaging of CP loaded SLNs exhibited spherical shape of SLNs. 
Drug release from SLNs dispersion and CP suspension showed a 
sustained release of the drug over a prolonged period of time as 
compared to free drug. Drug release from SLNs based suspension 
followed Higuchi model. Stability studies indicate a significant 
change in PS, when stored at room temperature.  
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